Study Name/Phase Type Sponsor Population (Gender/Age) Enrolled. (Retention rate) Period
1 Carraguard/Phase III Microbicide PC ♀ 18-40 yrs 2402 (86%) 2004-2007
2 FEM PreP/Phase III Oral Prep FHI360 ♀ 18-35 yrs 764 (87.5%) 2009-2012
3 ACASI/Phase II Behavioral PC ♀ 18-40 yrs 200 (100%) 2007
4 SBC preparedness /Phase III Mapping FHI360 >1000 (N/A) 2009-2012
5 HSV 2/Phase III HSV2 Treatment Novartis ♀ ≥18 yrs 8 (N/A) 2008-2009
6 Diabetic Peripheral Neuropathic/Phase III Observational Pfizer ♂/♀ ≥18 yrs 8 (100%) 2011
7 Tyrosur study/Phase III Wound Healing Engelhard Arzneimittel ♂/♀ ≥12 yrs 55 (100%) 2012-2013
8 Impetigo/Phase III Impetigo Treatment Galderma Inc ♂/♀ ≥18 yrs 49 (100%) 2012-2013
9 PrEP & Risk Compensation/Phase III Behavioral FHI 360 ♀ 18-35 yrs 540 (100%) 2012-2013
10 PreP & Adherence /Phase III Behavioral FHI 360 ♀ 18-35 yrs 229 (100%) 2013
11 TESEC 05/Phase III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 164 (98.8%) 2012-2013
12 TESEC 07/Phase II/III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 64 (99%) 2012-2013
13 FACTS 001/Phase III Microbicide CONRAD ♀ 18-30 yrs 460 (89%) 2011-2015
14  Group B streptococcus/Phase III Observational Novartis ♀ ≥18 yrs 501 (N/A) 2013-2015
15 CE/049/ACT/Phase IV Wound Healing  Smith & Nephew ♂/♀ 0-65 yrs 12 (100%) 2015
16 HVTN 100/Phase I/II (Part A) HIV Vaccine DAIDS ♂/♀ 18-35 yrs 44 (100%) 2015 – 2017
17 TRIO MPT Acceptability RTI ♀ 18-35 yrs 140 (97.9%) 2015 -2016
18 RSV (Season 1)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 36 (100%) 2015 -2017
19 NC006 (STAND)/Phase III TB Drug therapy TB alliance ♂/♀ ≥18 yrs 12 (80%) 2015 -2017
20 ASP-CRO-MIC-004/ Bioequivalence Oral Candida Treatment Aspen ♂/♀ ≥18 yrs 05 (80%) 2016 -2017